Rachel Richman
Overview
Rachel Bogin is an associate in the International Trade and White Collar and Regulatory Enforcement practices in Crowell & Moring’s Washington, D.C. office. Rachel is experienced in analyzing global sanctions and export control regimes to provide compliance guidance, examining domestic import regulations, and providing client representation in government investigations.
Career & Education
- Department of Commerce
Law Clerk, Commercial Law Development Program, 2023 - Securities and Exchange Commission
Law Clerk, Division of Enforcement, FCPA Unit, 2022 - New York
Law Clerk, Medicaid Fraud Control Unit, Office of the New York Attorney General, 2022
- Department of Commerce
Jacob Burns Community Legal Clinics, Criminal Defense and Justice Clinic, 2024
- The George Washington University, J.D., 2024
- Tulane University, B.S., cum laude, in legal studies in business, minor in art history, 2020
- District of Columbia
- Russian
- Hebrew
Rachel's Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Client Alert | 8 min read | 10.01.25
Insights
- |
10.07.25
Crowell & Moring’s International Trade Law
- |
07.07.25
Crowell & Moring’s International Trade Law
Rachel's Insights
Client Alert | 3 min read | 01.21.26
Atlantic Biologicals Opioid DPA: DOJ Continues Ramp Up of Criminal Corporate Healthcare Enforcement
On January 13, 2026, Miami-based pharmaceutical wholesaler Atlantic Biologicals Corporation entered into a two-year DPA, admitting to conspiracy to distribute and dispense controlled substances, including more than 14 million opioid doses to “pill mill” pharmacies in Texas at a markup. The DOJ and DEA underscored the company’s deliberate evasion of compliance checks and disregard for red flags signaling diversion.
Client Alert | 8 min read | 10.01.25
